Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
187.31B
Market cap187.31B
Price-Earnings ratio
23.97
Price-Earnings ratio23.97
Dividend yield
2.84%
Dividend yield2.84%
Average volume
3.84M
Average volume3.84M
High today
$349.40
High today$349.40
Low today
$345.01
Low today$345.01
Open price
$348.29
Open price$348.29
Volume
1.03M
Volume1.03M
52 Week high
$391.29
52 Week high$391.29
52 Week low
$267.83
52 Week low$267.83

Stock Snapshot

With a market cap of 187.31B, Amgen(AMGN) trades at $347.05. The stock has a price-to-earnings ratio of 23.97 and currently yields dividends of 2.84%.

On 2026-06-23, Amgen(AMGN) stock moved within a range of $345.01 to $349.40. With shares now at $347.05, the stock is trading +0.6% above its intraday low and -0.7% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 1.03M, versus its average volume of 3.84M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $267.83.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $267.83.

AMGN News

Simply Wall St 2h
Amgen Stock Could Be 2.1% Undervalued After Patent Verdict

Harbour BioMed’s jury victory in a high profile patent case against Amgen (AMGN) has put fresh legal risk in focus, as the verdict confirmed willful infringemen...

Amgen Stock Could Be 2.1% Undervalued After Patent Verdict
Nasdaq 4d
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Key Points Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-...

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Analyst ratings

50%

of 36 ratings
Buy
38.9%
Hold
50%
Sell
11.1%

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.